Akèy › Maladi fwa steatotik › Lwizyàn
Etid klinik pou Maladi fwa steatotik nan Lwizyàn
11 etid pou Maladi fwa steatotik ap chèche patisipan nan sit nan Lwizyàn.
Vil nan Lwizyàn
Tèks ofisyèl etid la (Anglè)
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Lafayette
- 89bio Clinical Study Site, Lake Charles
- 89bio Clinical Study Site, West Monroe
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Oct 5, 2026 · NCT06419374A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Covington
- 89bio Clinical Study Site, Houma
- 89bio Clinical Study Site, Lake Charles
- ak 2 plis
Ap rekriteFaz 3
Laj 18 a 80 · Tout sèks · Mizajou Oct 5, 2026 · NCT06318169A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
- Tandem Clinical Research, Plaza II, Metairie
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 29, 2026 · NCT07527910A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
- Tandem Clinical Research, Metairie
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT05519475A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Delta Research Partners of Bastrop, LLC, Bastrop
- Tandem Clinical Research, Marrero
- Care Access - New Iberia, New Iberia
- ak 2 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Bastrop
- Akero Clinical Study Site, Covington
- Akero Clinical Study Site, Houma
- ak 5 plis
Ap rekriteFaz 3
Laj 18 a 80 · Tout sèks · Mizajou Sep 21, 2026 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, Marrero
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 17, 2026 · NCT07221188A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Tandem Clinical Research, Covington
- Tandem Clinical Research, Houma
- Tandem Clinical Research GI, LLC, Marrero
- ak 4 plis
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 9, 2026 · NCT07288138A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, Marrero
Ap rekriteFaz 2
Laj 18 a 70 · Tout sèks · Mizajou Aug 3, 2026 · NCT06613698A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Bastrop
- GSK Investigational Site, Marrero
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Jul 27, 2026 · NCT07221227A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Tandem Clinical Research, Marrero
Ap rekriteFaz 1/2Volontè an sante akeyi
Laj 18 a 75 · Tout sèks · Mizajou Apr 16, 2026 · NCT05648214Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.